Robin L. Washington to Join Gilead as Senior Vice President and Chief Financial Officer

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Robin L.
Washington will join the company in May 2008 as Senior Vice President
and Chief Financial Officer. Ms. Washington will report to John F.
Milligan, PhD, Gilead´s Chief Operating Officer. She will oversee
Gilead´s worldwide Finance and Investor Relations functions and will
serve as a member of Gilead´s senior leadership team.

"We are very excited to have a person with Robin´s deep financial
expertise join the Gilead team," said Dr. Milligan. "Robin´s
background will bring a unique perspective and knowledge base to
Gilead, and I look forward to working closely with her as we continue
to grow the Gilead organization and deliver more products to patients
around the world."

Ms. Washington most recently served as Chief Financial Officer of
Hyperion Solutions, an enterprise software company that was acquired
by Oracle Corporation in March 2007. In this role, she was responsible
for all financial operations, investor relations and information
technology infrastructure and systems for Hyperion. Prior to Hyperion
Solutions, Ms. Washington spent nearly 10 years at PeopleSoft, a
provider of enterprise application software, most recently in the role
of Senior Vice President and Corporate Controller, a position she held
from 1999 through 2005. She previously was a Director of Finance for
Tandem Computers, an Accounting Analyst for the Federal Reserve Bank
of Chicago and a Senior Auditor for Deloitte & Touche.

Ms. Washington holds a bachelor´s degree in business
administration from the University of Michigan and a MBA from
Pepperdine University.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers

develops and commercializes innovative therapeutics in areas of unmet
medical need. The company´s mission is to advance the care of patients
suffering from life-threatening diseases worldwide. Headquartered in
Foster City, California, Gilead has operations in North America

Europe and Australia.

This press release includes forward-looking statements, within the
meaning of the Private Securities Litigation Reform Act of 1995, that
are subject to risks, uncertainties and other factors, including risks
that Gilead will not experience continued growth in the future. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in the Gilead Annual
Report on Form 10-K for the year ended December 31, 2007 as filed with
the U.S. Securities and Exchange Commission. All forward-looking
statements are based on information currently available to Gilead and
Gilead assumes no obligation to update any such forward-looking
statements.

For more information on Gilead Sciences, please visit the
company´s website at www.gilead.com or call Gilead Public Affairs at
1-800-GILEAD-5 or 1-650-574-3000.